Bailard Inc. Acquires Shares of 16,900 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Bailard Inc. bought a new position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 16,900 shares of the company’s stock, valued at approximately $115,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in YMAB. China Universal Asset Management Co. Ltd. bought a new stake in Y-mAbs Therapeutics during the 4th quarter worth about $34,000. SG Americas Securities LLC bought a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $100,000. Exchange Traded Concepts LLC increased its holdings in shares of Y-mAbs Therapeutics by 29.4% in the third quarter. Exchange Traded Concepts LLC now owns 20,971 shares of the company’s stock valued at $114,000 after purchasing an additional 4,763 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Y-mAbs Therapeutics by 4.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock valued at $178,000 after purchasing an additional 1,089 shares in the last quarter. Finally, Sapient Capital LLC bought a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $298,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Stock Up 5.4 %

Shares of Y-mAbs Therapeutics stock opened at $15.50 on Tuesday. The business has a fifty day simple moving average of $15.74 and a 200 day simple moving average of $10.58. Y-mAbs Therapeutics, Inc. has a 12 month low of $4.60 and a 12 month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.17. The firm had revenue of $23.36 million for the quarter, compared to analysts’ expectations of $21.72 million. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. As a group, equities research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Analyst Ratings Changes

YMAB has been the topic of a number of recent research reports. Canaccord Genuity Group increased their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Wedbush reiterated an “outperform” rating and issued a $18.00 price target (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. BMO Capital Markets lifted their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research report on Monday, March 4th. Finally, HC Wainwright upped their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $16.57.

Insider Buying and Selling

In related news, SVP Vignesh Rajah sold 1,711 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total transaction of $28,282.83. Following the completion of the transaction, the senior vice president now owns 33,889 shares in the company, valued at $560,185.17. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 21.50% of the stock is owned by insiders.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.